Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.

Komet-007 showed no differentiation syndrome, but the group didn’t disclose data on menin inhibitor-experienced patients.

Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?

But JNJ-75276617 still has much to prove.

With revumenib’s broader coverage Syndax tries to gain ground on Kura’s ziftomenib, but hits a new snag.